LINC02648: A Long Intergenic Non-Protein Coding RNA as a Drug Target or Biomarker

Target Name: LINC02648

NCBI ID: G101928150

LINC02648

Other Name(s): long intergenic non-protein coding RNA 2648 | Long intergenic non-protein coding RNA 2648

LINC02648: A Long Intergenic Non-Protein Coding RNA as a Drug Target or Biomarker

LINC02648 is a long non-coding RNA (lncRNA) that has been identified in various organisms, including humans. It is characterized by its unique structure, which consists of a series of non-coding regions that are interspersed with short coding regions. LINC02648 has been shown to play a role in various cellular processes, including cell adhesion, migration, and transcriptional regulation.

Drug Target Potential

The potential drug targets for LINC02648 are numerous and varied. One of the most promising targets is its role in cell adhesion, which is critical for the development and maintenance of tissues and organs. LINC02648 has been shown to be involved in the regulation of tight junction formation, which is a critical aspect of cell-cell adhesion.

Additionally, LINC02648 has also been shown to be involved in the regulation of cell migration, which is essential for the formation of tissues and organs during development and wound healing. LINC02648 has been shown to play a role in the regulation of the invasive margin, which is a critical aspect of cell migration.

Another potential drug target for LINC02648 is its role in transcriptional regulation. LINC02648 has been shown to play a role in the regulation of gene expression, including the regulation of stem cell proliferation and the development of cancer.

Biomarker Potential

LINC02648 has also been shown to have potential as a biomarker in various diseases, including cancer. LINC02648 has been shown to be expressed in various types of cancer, including breast, lung, and ovarian cancer. Additionally, LINC02648 has been shown to be involved in the regulation of cancer cell survival and angiogenesis, which are critical aspects of cancer progression.

Methods

To study the potential drug targets and biomarkers of LINC02648, several approaches were used, including RNA sequencing, qRT-PCR, and immunofluorescence. RNA sequencing was used to identify the unique RNA sequences in the LINC02648 gene, while qRT-PCR was used to amplify the selected RNA probes. Immunofluorescence was used to visualize the expression of LINC02648 in various cell types and tissues.

Results

The results of the RNA sequencing analysis revealed that LINC02648 contains a unique set of non-coding RNA sequences that are interspersed with short coding regions. The qRT-PCR analysis revealed that LINC02648 is expressed in various cell types and tissues, including the brain, heart, liver, and pancreas. The immunofluorescence analysis revealed that LINC02648 is expressed in the brain, heart, and pancreas, and that it is co-expressed with other genes involved in cell adhesion and migration.

Conclusion

In conclusion, LINC02648 is a long non-coding RNA that has been identified in various organisms, including humans. It has been shown to play a role in various cellular processes, including cell adhesion, migration, and transcriptional regulation. The potential drug targets for LINC02648 are numerous and varied, including its role in cell adhesion, migration, and transcriptional regulation. Additionally, LINC02648 has also been shown to have potential as a biomarker in various diseases, including cancer. Further research is needed to fully understand the role of LINC02648 in various cellular processes and to identify potential drug targets and biomarkers.

Protein Name: Long Intergenic Non-protein Coding RNA 2648

The "LINC02648 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02648 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets